The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia

Journal of Human Hypertension

Volumn 26, Issue 4, 2012, Pages 236-241

  Aggarwal, P K ^a   Chandel, N ^a   Jain, V ^a   Jha, V ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

endothelin 1; placental growth factor; preeclampsia; pregnancy; soluble endoglin; soluble fms like tyrosine kinase 1

Indexed keywords

ENDOGLIN; ENDOTHELIN 1; PLACENTAL GROWTH FACTOR; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY; PRIMIGRAVIDA; PROTEINURIA;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ENDOTHELIN-1; FEMALE; HUMANS; HYPERTENSION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84858698421     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.29     Document Type: Article

References (30)

1. Noris M, Perico N, Remuzzi G. Mechanisms of disease: Pre-eclampsia. Nat Clin Pract Nephrol 2005; 1: 98-114; quiz 120.
2. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799. (Pubitemid 40311367)
3. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294: H541-H550. (Pubitemid 351253261)
4. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 2001; 38: 718-722.
5. Gu Y, Lewis DF, Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 2008; 93: 260-266.
6. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658. (Pubitemid 36278583)
7. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649. (Pubitemid 43865232)
8. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005. (Pubitemid 44343543)
9. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683. (Pubitemid 38364626)
10. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 2000; 183: 1554-1557. (Pubitemid 32061224)
11. Tsatsaris V, Goffin F, Munaut C, Brichant JF, Pignon MR, Noel A et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: Pathophysiological consequences. J Clin Endocrinol Metab 2003; 88: 5555-5563. (Pubitemid 37452769)
12. Aggarwal PK, Jain V, Srinivasan R, Jha V. Maternal EDN1 G5665T polymorphism influences circulating endothelin-1 levels and plays a role in determination of preeclampsia phenotype. J Hypertens 2009; 27: 2044-2050.
13. Barden AE, Herbison CE, Beilin LJ, Michael CA, Walters BN, Van Bockxmeer FM. Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens 2001; 19: 1775-1782. (Pubitemid 32924943)
14. Clark BA, Halvorson L, Sachs B, Epstein FH. Plasma endothelin levels in preeclampsia: Elevation and correlation with uric acid levels and renal impairment. Am J Obstet Gynecol 1992; 166: 962-968.
15. Greer IA, Leask R, Hodson BA, Dawes J, Kilpatrick DC, Liston WA. Endothelin, elastase, and endothelial dysfunction in pre-eclampsia. Lancet 1991; 337: 558.
16. Taylor RN, Varma M, Teng NN, Roberts JM. Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies. J Clin Endocrinol Metab 1990; 71: 1675-1677. (Pubitemid 120032795)
17. Karumanchi SA, Epstein FH. Placental ischemia and soluble fms-like tyrosine kinase 1: Cause or consequence of preeclampsia? Kidney Int 2007; 71: 959-961. (Pubitemid 46742004)
18. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol 1997; 272: R441-R463.
19. Williams DJ, Vallance PJ, Neild GH, Spencer JA, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997; 272: H748-H752.
20. Alexander BT, Rinewalt AN, Cockrell KL, Massey MB, Bennett WA, Granger JP. Endothelin type a receptor blockade attenuates the hypertension in response to chronic reductions in uterine perfusion pressure. Hypertension 2001; 37: 485-489. (Pubitemid 32199016)
21. Roberts L, LaMarca BB, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion. Hypertension 2006; 47: 615-618. (Pubitemid 43843885)
22. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50: 1142-1147. (Pubitemid 350172938)
23. Gilbert JS, Gilbert SA, Arany M, Granger JP. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension 2009; 53: 399-403.
24. Collino F, Bussolati B, Gerbaudo E, Marozio L, Pelissetto S, Benedetto C et al. Preeclamptic sera induce nephrin shedding from podocytes through endothelin-1 release by endothelial glomerular cells. Am J Physiol Renal Physiol 2008; 294: F1185-F1194.
25. Sugimoto H, Hamano Y, Charytan D, Cosgrove D, Kieran M, Sudhakar A et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608. (Pubitemid 36800018)
26. Murphy SR, LaMarca BB, Cockrell K, Granger JP. Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension 2010; 55: 394-398.
27. Bridges JP, Gilbert JS, Colson D, Gilbert SA, Dukes MP, Ryan MJ et al. Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens 2009; 22: 564-568.
28. Sandrim VC, Palei AC, Cavalli RC, Araujo FM, Ramos ES, Duarte G et al. Vascular endothelial growth factor genotypes and haplotypes are associated with preeclampsia but not with gestational hypertension. Mol Hum Reprod 2009; 15: 115-120.
29. Aggarwal PK, Jain V, Jha V. Endothelial nitric oxide synthase, angiotensin-converting enzyme and angiotensinogen gene polymorphisms in hypertensive disorders of pregnancy. Hypertens Res 2010; 33: 473-477.
30. Wang CN, Chang SD, Peng HH, Lee YS, Chang YL, Cheng PJ et al. Change in amniotic fluid levels of multiple anti-angiogenic proteins before development of preeclampsia and intrauterine growth restriction. J Clin Endocrinol Metab 2010; 95: 1431-1441.